19
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          SARS-CoV-2 infection proceeds through the binding of viral surface spike protein to the human ACE2 protein. The global spread of the infection has led to the emergence of fitter and more transmissible variants with increased adaptation both in human and nonhuman hosts. Molecular simulations of the binding event between the spike and ACE2 proteins offer a route to assess potential increase or decrease in infectivity by measuring the change in binding strength. We trained a neural network model that accurately maps simulated binding energies to experimental changes in binding strength upon amino acid changes in the spike protein. This computational workflow can be used to a priori assess currently circulating and prospectively future viral variants for their affinity for hACE2.

          Abstract

          The association of the receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein with human angiotensin-converting enzyme 2 (hACE2) represents the first required step for cellular entry. SARS-CoV-2 has continued to evolve with the emergence of several novel variants, and amino acid changes in the RBD have been implicated with increased fitness and potential for immune evasion. Reliably predicting the effect of amino acid changes on the ability of the RBD to interact more strongly with the hACE2 can help assess the implications for public health and the potential for spillover and adaptation into other animals. Here, we introduce a two-step framework that first relies on 48 independent 4-ns molecular dynamics (MD) trajectories of RBD−hACE2 variants to collect binding energy terms decomposed into Coulombic, covalent, van der Waals, lipophilic, generalized Born solvation, hydrogen bonding, π−π packing, and self-contact correction terms. The second step implements a neural network to classify and quantitatively predict binding affinity changes using the decomposed energy terms as descriptors. The computational base achieves a validation accuracy of 82.8% for classifying single–amino acid substitution variants of the RBD as worsening or improving binding affinity for hACE2 and a correlation coefficient of 0.73 between predicted and experimentally calculated changes in binding affinities. Both metrics are calculated using a fivefold cross-validation test. Our method thus sets up a framework for screening binding affinity changes caused by unknown single– and multiple–amino acid changes offering a valuable tool to predict host adaptation of SARS-CoV-2 variants toward tighter hACE2 binding.

          Related collections

          Most cited references103

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A pneumonia outbreak associated with a new coronavirus of probable bat origin

          Since the outbreak of severe acute respiratory syndrome (SARS) 18 years ago, a large number of SARS-related coronaviruses (SARSr-CoVs) have been discovered in their natural reservoir host, bats 1–4 . Previous studies have shown that some bat SARSr-CoVs have the potential to infect humans 5–7 . Here we report the identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China. The epidemic, which started on 12 December 2019, had caused 2,794 laboratory-confirmed infections including 80 deaths by 26 January 2020. Full-length genome sequences were obtained from five patients at an early stage of the outbreak. The sequences are almost identical and share 79.6% sequence identity to SARS-CoV. Furthermore, we show that 2019-nCoV is 96% identical at the whole-genome level to a bat coronavirus. Pairwise protein sequence analysis of seven conserved non-structural proteins domains show that this virus belongs to the species of SARSr-CoV. In addition, 2019-nCoV virus isolated from the bronchoalveolar lavage fluid of a critically ill patient could be neutralized by sera from several patients. Notably, we confirmed that 2019-nCoV uses the same cell entry receptor—angiotensin converting enzyme II (ACE2)—as SARS-CoV.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

            Summary The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

              Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.)
                Bookmark

                Author and article information

                Journal
                Proc Natl Acad Sci U S A
                Proc Natl Acad Sci U S A
                pnas
                PNAS
                Proceedings of the National Academy of Sciences of the United States of America
                National Academy of Sciences
                0027-8424
                1091-6490
                19 October 2021
                29 September 2021
                29 September 2021
                : 118
                : 42
                : e2106480118
                Affiliations
                [1] aDepartment of Chemical Engineering, The Pennsylvania State University , University Park, PA 16802;
                [2] bThe Bioinformatics and Genomics Program, Huck Institutes of the Life Sciences, The Pennsylvania State University , University Park, PA 16802;
                [3] cDepartment of Veterinary and Biomedical Sciences, The Pennsylvania State University , University Park, PA 16802;
                [4] dAnimal Diagnostic Laboratory, Department of Veterinary and Biomedical Sciences, The Pennsylvania State University , University Park, PA 16802;
                [5] eCenter for Infectious Disease Dynamics, The Pennsylvania State University , University Park, PA 16802
                Author notes
                2To whom correspondence may be addressed. Email: costas@ 123456psu.edu or skuchipudi@ 123456psu.edu .

                Edited by Gerhard Hummer, Max Planck Institute for Biophysics, Frankfurt am Main, Germany, and accepted by Editorial Board Member Angela M. Gronenborn August 23, 2021 (received for review April 6, 2021)

                Author contributions: C.C., V.S.B., S.V.K., and C.D.M. designed research; C.C., V.S.B., and D.B. performed research; C.C., V.S.B., and D.B. analyzed data; and C.C., V.S.B., R.C., V.S.C., R.H.N., A.G., N.R.B., K.V., M.S.N., S.V.K., and C.D.M. wrote the paper.

                1C.C. and V.S.B. contributed equally to this work.

                Author information
                https://orcid.org/0000-0002-8316-7898
                https://orcid.org/0000-0003-0084-3975
                https://orcid.org/0000-0003-4877-0920
                https://orcid.org/0000-0003-4522-6911
                https://orcid.org/0000-0002-3320-8639
                https://orcid.org/0000-0002-3102-7447
                https://orcid.org/0000-0003-0901-3775
                https://orcid.org/0000-0002-5690-3300
                https://orcid.org/0000-0003-4686-8414
                https://orcid.org/0000-0002-1508-1398
                Article
                202106480
                10.1073/pnas.2106480118
                8594574
                34588290
                2d82d0ca-539c-431e-ab63-4e468f774608
                Copyright © 2021 the Author(s). Published by PNAS.

                This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

                History
                : 23 August 2021
                Page count
                Pages: 10
                Funding
                Funded by: The Center for Bioenergy Innovation, DOE
                Award ID: DE-AC05-000R22725
                Award Recipient : Veda Sheersh Boorla Award Recipient : Deepro Banerjee Award Recipient : Kurt Vandegrift Award Recipient : Suresh V Kuchipudi Award Recipient : Costas D Maranas
                Funded by: U.S. Department of Agriculture (USDA) 100000199
                Award ID: 2020-67015-32175
                Award Recipient : Chen Chen Award Recipient : Victoria S Cavener Award Recipient : Ruth H Nissly Award Recipient : Abhinay Gontu Award Recipient : Nina R Boyle Award Recipient : Meera Surendran Nair Award Recipient : Suresh V Kuchipudi Award Recipient : Costas D Maranas
                Funded by: National Science Foundation Ecology and Evolution of Infectious Diseases
                Award ID: 1619072
                Award Recipient : Veda Sheersh Boorla Award Recipient : Deepro Banerjee Award Recipient : Kurt Vandegrift Award Recipient : Suresh V Kuchipudi Award Recipient : Costas D Maranas
                Funded by: Huck Institute of Life Sciences, Pennsylvania State University
                Award ID: Seed grant
                Award Recipient : Veda Sheersh Boorla Award Recipient : Deepro Banerjee Award Recipient : Kurt Vandegrift Award Recipient : Suresh V Kuchipudi Award Recipient : Costas D Maranas
                Categories
                408
                530
                Physical Sciences
                Biophysics and Computational Biology
                Biological Sciences
                Biophysics and Computational Biology
                Custom metadata
                free

                sars-cov-2,human ace2,binding affinity,mm-gbsa,neural network

                Comments

                Comment on this article